„Terapia szokowa”, czyli agoniści receptor 5-HT2A w leczeniu depresji i lęku
Loading...
Terapia_szokowa_czyli_zastosowanie_agonistów_receptora_5HT2A_w _leczeniu_depresji.pdf (732.16 KB)
Authors
Date
2017-12
Journal Title
Journal ISSN
Volume Title
Publisher
SKN Uroboros
Using this material is possible in accordance with the relevant provisions of fair use or other exceptions provided by law. Other use requires the consent of the holder.
Abstract
The most widespread ailment that affects people nowadays are depressive and anxiety disorder, which may concern even 20% of the population. Profits of pharmaceutical companies from drug trade on theseailments are among the biggest, which shows a large scale of the problem. The most commonly useddrugs in these cases are SSRIs - selective serotonin reuptake inhibitors, whose antidepressant andanxiolytic effects are mainly based on change in density of some receptors, which translates into areduction intensity of emotions. However, recently researchers have turned to drugs that acts reverse to SSRIs. These substances are psychedelics, for instance LSD, psilocybin and ayahuasca, which are 5HT2A receptor agonists in the central nervous system. It turns out that substances which almost alcountries of the world are illegal, properly used can have therapeutic properties, and this action is based not on suppressing emotions and thoughts, but on increasing their intensity. This allows in some wayunderstand and work on the disorder. Following text presents a brief description of depression andanxiety, psychedelics pharmacodynamics and safety of their use. Then we discussed some of thecompounds most commonly used in research and possible scientific explanations why they work therapeutically. There are presented also SSRIs mechanism of action and their comparison with psychedelics, both in terms of receptor activity or different molecules in the brain, as well as in subjective perceptions of the effects.